405 related articles for article (PubMed ID: 25129490)
1. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
2. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
4. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
5. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
9. Current update on eosinophilic lung diseases and anti-IL-5 treatment.
Samitas K; Rådinger M; Bossios A
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):189-205. PubMed ID: 21824072
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils in Health and Disease: A State-of-the-Art Review.
Wechsler ME; Munitz A; Ackerman SJ; Drake MG; Jackson DJ; Wardlaw AJ; Dougan SK; Berdnikovs S; Schleich F; Matucci A; Chanez P; Prazma CM; Howarth P; Weller PF; Merkel PA
Mayo Clin Proc; 2021 Oct; 96(10):2694-2707. PubMed ID: 34538424
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted therapies for eosinophil-associated diseases and allergy.
Radonjic-Hoesli S; Valent P; Klion AD; Wechsler ME; Simon HU
Annu Rev Pharmacol Toxicol; 2015; 55():633-56. PubMed ID: 25340931
[TBL] [Abstract][Full Text] [Related]
14. Targeted Molecular Therapies in Allergy and Rhinology.
Damask CC; Ryan MW; Casale TB; Castro M; Franzese CB; Lee SE; Levy JM; Lin SY; Lio PA; Peters AT; Platt MP; White AA
Otolaryngol Head Neck Surg; 2021 Jan; 164(1_suppl):S1-S21. PubMed ID: 33138725
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
16. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
17. Eosinophils and eosinophilic immune dysfunction in health and disease.
Jackson DJ; Akuthota P; Roufosse F
Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35082127
[TBL] [Abstract][Full Text] [Related]
18. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
Schmid-Grendelmeier P; Altznauer F; Fischer B; Bizer C; Straumann A; Menz G; Blaser K; Wüthrich B; Simon HU
J Immunol; 2002 Jul; 169(2):1021-7. PubMed ID: 12097410
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
Roufosse F
Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
[TBL] [Abstract][Full Text] [Related]
20. Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders.
Dellon ES; Simon D; Wechsler ME
J Allergy Clin Immunol Pract; 2022 May; 10(5):1169-1176. PubMed ID: 35167955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
